-
Protocol Number:
BO22280
Product Name:
pertuzumab
[pertuzumab]
Date of Report:
01.05.2012
Phase:
II
A randomised, multicentre, multinational Phase II study to evaluate pertuzumab in combination with trastuzumab given either concomitantly or sequentially with standard anthracycline-based chemotherapy or concomitantly with a non-anthracycline-based chemotherapy regimen, as neoadjuvant therapy for patients with locally advanced, inflammatory or early stage HER2-positive breast cancer.
-
Protocol Number:
WO20698
Product Name:
pertuzumab
[pertuzumab]
Date of Report:
01.12.2012
Phase:
III
A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of Herceptin + docetaxel + pertuzumab versus Herceptin + docetaxel + placebo in previously untreated HER2-positive metastatic breast cancer
-
Protocol Number:
WO20697
Product Name:
pertuzumab
[pertuzumab]
Date of Report:
01.06.2011
Phase:
II
A randomized, open label study to compare the complete pathological response rate achieved with 4 combinations of Herceptin, docetaxel and pertuzumab in patients with locally advanced, inflammatory or early stage HER2 positive breast cancer
-
Protocol Number:
BO17931
Product Name:
pertuzumab
[pertuzumab]
Date of Report:
01.07.2011
Phase:
II
A randomized, open-label study of the effect of Omnitarg in combination with carboplatin-based chemotherapy versus carboplatin-based therapy alone on treatment response in patients with platinum-sensitive recurrent ovarian cancer
-
Protocol Number:
MO22324
Product Name:
pertuzumab
Date of Report:
To be Published
Phase:
II
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
-
Protocol Number:
BO25126
Product Name:
pertuzumab
Date of Report:
To be Published
Phase:
III
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
-
Protocol Number:
MO28047
Product Name:
pertuzumab
Date of Report:
To be Published
Phase:
III
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)
-
Protocol Number:
MO27782
Product Name:
pertuzumab
Date of Report:
To be Published
Phase:
II
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
-
Protocol Number:
MO28113
Product Name:
pertuzumab
Date of Report:
To be Published
Phase:
II
A Study of Pertuzumab in Combination With Standard Chemotherapy in Women With Recurrent Platinum-Resistant Epithelian Ovarian Cancer and Low HER3 mRNA Expression
-
Protocol Number:
BP27836
Product Name:
pertuzumab
Date of Report:
To be Published
Phase:
II
A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients with HER2-Positive Advanced Gastric Cancer
-
Protocol Number:
MO27775
Product Name:
pertuzumab
Date of Report:
To be Published
Phase:
II
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer
-
Protocol Number:
BO17004
Product Name:
pertuzumab
[pertuzumab]
Date of Report:
01.01.2006
Phase:
II
An open-label, phase II, multicenter study to evaluate the efficacy and safety of a recombinant humanized antibody to HER2 (pertuzumab) administered every 3 weeks to patients with hormone-refractory prostate cancer who have not been treated with chemotherapy.
-
Protocol Number:
BO16934
Product Name:
pertuzumab
[pertuzumab]
Date of Report:
01.11.2005
Phase:
II
Open label, phase II, multicenter, randomized study of efficacy and safety for two different doses of a recombinant humanized antibody to HER2 (rhuMAb 2C4) administered every 3 weeks to patients with metastatic breast cancer with low expression of HER2.
-
Protocol Number:
WO20024
Product Name:
pertuzumab
[pertuzumab]
Date of Report:
01.06.2009
Phase:
I
Phase Ib, open-label, multi-center study of the combination of pertuzumab and erlotinib in patients with locally advanced or metastatic (stage IIIb/IV) NSCLC after failure of at least one prior chemotherapy regimen.